key: cord-0775194-ihpc0hdj
authors: Ling, Ryan Ruiyang; Sim, Jackie Jia Lin; Tan, Felicia Liying; Tai, Bee Choo; Syn, Nicholas; Mucheli, Sharavan Sadasiv; Fan, Bingwen Eugene; Mitra, Saikat; Ramanathan, Kollengode
title: Convalescent plasma for patients hospitalised with Coronavirus disease 2019: A meta-analysis with trial sequential analysis of randomised controlled trials
date: 2021-10-10
journal: Transfus Med Rev
DOI: 10.1016/j.tmrv.2021.09.001
sha: 025b56558014f13fe8becb339be335e4ef51fb08
doc_id: 775194
cord_uid: ihpc0hdj

Current evidence from randomised controlled trials (RCTs) and systematic reviews on the utility of convalescent plasma (CP) in patients with coronavirus disease 2019 (COVID-19) suggests a lack of benefit. We conducted an updated meta-analysis of RCTs with trial sequential analysis to investigate whether convalescent plasma is futile in reducing mortality in patients hospitalized with COVID-19. We searched six databases from 1(st) December 2019 to 1(st) August 2021 for RCTs comparing the use of CP with standard of care or transfusion of non-CP standard plasma in patients with COVID-19. The risk of bias was assessed using the Cochrane Risk-of-Bias 2 Tool. Random effects (DerSimonian and Laird) meta-analyses were conducted. The primary outcome was the aggregate risk for in-hospital mortality between both arms. We conducted a trial sequential analysis (TSA) based on the pooled relative risks (RRs) for in-hospital mortality. Secondary outcomes included the pooled RR for receipt of mechanical ventilation and mean difference in hospital length of stay. We included 18 RCTs (8702 CP, 7906 control). CP was not associated with a significant mortality benefit (RR: 0.95, 95%-CI: 0.86-1.04, p=0.27, high certainty). Subgroup analysis did not find any significant differences (p(interaction)=0.30) between patients who received CP within 8 days of symptom onset (RR: 0.97, 95%-CI: 0.79-1.19, p=0.80), or after 8 days (RR: 0.79, 95%-CI: 0.57-1.10, p=0.16). TSA based on a RR reduction of 10% from a baseline mortality of 20% found that CP was not effective, with the pooled effect within the boundary for futility. CP did not significantly reduce the requirement for mechanical ventilation (RR: 1.00, 95%-CI: 0.91-1.10, p=0.99, moderate certainty) or hospital length of stay (+1.32, 95%-CI: -1.86 to +4.52, p=0.42, low certainty). CP does not improve relevant clinical outcomes in patients with COVID-19, especially in severe disease. The pooled effect of mortality was within the boundary of futility, suggesting the lack of benefit of CP in patients hospitalised with COVID-19.

The coronavirus disease 2019 (COVID-19) pandemic continues to progress, and a spike in cases has been noted worldwide since March 2021, with many countries experiencing a second or third wave. Healthcare systems have been burdened globally, and up to 20% of infected patients progress to severe disease and 5% require admission to the intensive care unit (ICU). [1] It has been reported that mortality rates of patients with severe COVID-19 reach up to 20%, [2] and as many as 45% of patients requiring invasive mechanical ventilation do not survive. [3] Several potential therapies have been investigated, but only glucocorticoids, interleukin-6 receptor antagonists, and monoclonal antibodies have shown some survival benefits till date. [4] [5] [6] Convalescent plasma (CP) is a potential therapy that has been previously investigated against other respiratory viruses. [7, 8] It supposedly engenders a temporary immune response against the viral particles, before the peak production of endogenous IgM and IgG antibodies by the native immune response is established in the patient. [9] The transient reduction in viral load reduces the stimulus for a hyperinflammatory cytokine storm that mediates further progression. Early administration of convalescent plasma in disease has been proven to be beneficial in some viral illnesses. [9, 10] Numerous observational studies, randomised controlled trials (RCTs) and systematic reviews have been published thus far in patients with COVID-19, [11, 12] with most recent reviews highlighting a lack of benefit of CP. [13] Multiple RCTs have been terminated early due to the decreasing prevalence of COVID-19, as well as refusal of consent from eligible patients. [14] [15] [16] [17] [18] As a result of this, the sample size of these RCTs are insufficient, and they are unable to provide strong evidence for or against CP in COVID- 19 . As such, we conducted a systematic review and meta-analysis of CP use in patients hospitalised with COVID- 19 . In addition to this, we performed a trial sequential analysis (TSA) via cumulative meta-analysis similar to interim analyses in RCTs, in order to assess the conclusiveness of the findings from our meta-analysis.

This study was registered with PROSPERO (CRD42021253826), and was conducted in adherence with the Preferred Reporting Items for Systematic Reviews and Meta-analyses Statement. [19] We searched MEDLINE, Embase, Cochrane, Scopus, MedRXiv and COVID-NMA databases from 1 st December 2019 to 1 st August 2021, using the following keywords and their variations: "COVID-19", "convalescent plasma", and "randomised controlled trials"

(Supplementary Data 1). We assessed all relevant studies and their citation lists to identify articles for inclusion.

We included all RCTs comparing the use of CP with standard of care or transfusion of non-CP standard plasma in 10 or more adult patients (18 years) hospitalised with severe COVID-19 reporting on in-hospital mortality, receipt of mechanical ventilation, or hospital length of stay. We excluded any non-human or paediatric studies (<18 years). In the case of overlapping patient data, we included the largest study and excluded any other overlapping studies. Three reviewers (RRL, JJLS, FLT) were involved in the screening process and any conflicts were resolved by a fourth reviewer (KR).

Study quality was assessed using the Cochrane Risk-of-Bias 2 tool for RCTs. [20] We used the Grading of Recommendations, Assessments, Developments and Evaluations (GRADE) approach to assess the certainty of evidence. [21] The assessment for risk of bias and certainty of evidence was conducted by three reviewers (RRL, JJS, FLT) independently, and conflicts were resolved by a fourth reviewer (KR)

The primary outcome for our meta-analysis is in-hospital mortality, and this is quantified based on the relative risk (RR) between the treatment versus control arms. Secondary outcomes included the receipt of mechanical ventilation, and the hospital length of stay. Other outcomes that were reported descriptively include the intensive care unit (ICU) length of stay, as well as any other adverse outcomes. Data were collected independently by four reviewers (RRL, JJLS, FLT, SM) using a prespecified datasheet, and conflicts were resolved by a fifth reviewer (KR). Data collection covered study characteristics, patient demographics, CP characteristics, mortality, and other relevant clinical outcomes (Supplementary Data 2).

We estimated the summary RRs for in-hospital mortality between the treatment and control arms for each study, and pooled them using random effects (DerSimonian and Laird) meta-analysis based on the Freeman Tukey double arcsine transformation. [22] [23] [24] Confidence intervals were computed using the Clopper-Pearson method. We assessed the possibility of publication bias via visual inspection of the funnel plot as well as Egger's regression test. Smallstudy effects were corrected using the random-effects trim-and-fill (R 0 estimator) procedure. A previous meta-analysis suggested the exclusion of the study by Agarwal et al. as majority of their patients had received low antibody titres, following which they found significant survival benefits. [12] To test this hypothesis, we conducted a sensitivity analysis excluding the study from the meta-analysis. Another sensitivity analysis was conducted by excluding any studies with high risks of bias.

To further elicit the effect of CP in COVID-19, we performed TSA using TSA v0.9.5.10 (www.ctu.dk/tsa), which combines an information size calculation for a meta-analysis with the threshold of statistical significance whenever an additional trial is included via cumulative meta-analysis. This is similar to group sequential monitoring boundaries in RCTs during interim analyses. The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial, which recruited patients to detect a RR reduction in mortality of 20%, did not find significant benefits from CP use. As such, in our meta-analysis, we sought to determine if CP had a significant benefit based on a smaller reduction in mortality. Using a type I error of 0.05 and a power of 0.80, we estimated the required information size assuming a RR reduction in mortality of 10% (which is closer to the pooled estimate in the meta-analysis) and a baseline in-hospital mortality rate of 20% as reported in the published literature for patients with severe COVID-19, anticipating low-moderate levels of heterogeneity. [2] Subgroup analysis was conducted based on the timing at which CP was given (within 8 days of symptom onset, and later than 8 days). We then pooled the RRs for receipt of mechanical ventilation, and the mean differences in hospital length of stay. Pooling of RRs was conducted with continuity correction by adding a constant of 0.5 to allow inclusion of studies with zero events. For continuous variables, means and standard deviations were derived from the aggregate data as per Wan et al. [25] Statistical heterogeneity was measured as part of the assessment of certainty of evidence outlined by the GRADE approach. Statistical analysis was conducted on R3.6.1. Nominal P<0.05 was considered statistically significant in our analysis.

We conducted several additional post-hoc analyses after extracting the data. Firstly, we conducted a subgroup analysis by regional variation as well as the risk of bias. Secondly, we conducted an additional trim-and-fill analysis for hospital length of stay in view of the significant publication bias (p egger <0.05).

Of 2721 references, we identified 118 potentially relevant studies for full-text evaluation. 20 RCTs were identified and 2 were excludedone compared the effects of early and deferred CP, [26] while another RCT did not report any of the prespecified primary or secondary outcomes. [27] In total, 18 RCTs comprising 16,608 hospitalised patients (CP vs control: 8702 vs 7906 patients) were included ( Figure 1 ). [14] [15] [16] [17] [18] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] 15 RCTs reported on 30-day mortality, and one RCT reported on 60-day mortality, [36] in-hospital mortality. [ Figure 2 , high certainty). While there was possible evidence of publication bias (p egger = 0.032), the pooled estimate remained relatively similar after correction of small-study effects using the trim-and-fill (R 0 estimator) procedure (RR: 0.98, 95%-CI: 0.86 to 1.11, p=0.71, Figure 3) . A futility analysis was conducted based on in-hospital mortality reported by 18 RCTs, the required information size was 17257. The cumulative Z-curve did not cross the boundaries for benefit or harm, and was within the boundary for futility (Figure 4) , suggesting the postulated benefit of CP is unlikely to be achieved with further randomisation of patients.

We then conducted a subgroup analysis based on the timing of CP (p interaction = 0.30 ) found no difference in the reduction in mortality across the individual subgroups.

Our analysis of the current literature suggests that CP does not appear to have any significant mortality benefits for patients hospitalised with COVID-19 (RR:

0.95, 95%-CI: 0.86 to 1.04, p=0.27), majority of whom had severe disease. Sensitivity analyses excluding Agarwal et al., [12, 28] studies with high risks of bias, [33] and studies that did not report on 30-day mortality did not significantly change the pooled estimate. Previously published meta-analyses suggested no survival benefits. [11] However, Klassen et al. found significant survival benefits after excluding one study where patients had received "low-levels" of antibodies during transfusion. [12, 28] While our meta-analysis had five newer RCTs included, our sensitivity analysis after excluding the study did not find any significant survival benefits for patients receiving CP.

Apart from its direct antiviral neutralising action, [9] CP therapy is postulated to provide additional benefit via immunomodulation of the infected host. [41] However, its effectiveness is confounded by the emergence of the newer alpha (B.1.1.7), gamma (P.1) and delta (B.1.617.2) variants, some of which may evade immune responses. Secondly, the lowest effective dose and neutralising antibody titre required for viral clearance remain uncertain. The mortality rates in patients hospitalised due to COVID-19 have been variable globally. While the RECOVERY trial, which enrolled the largest number of patients receiving CP, reported a 24% mortality in the control and intervention arms of predominantly severe COVID-19 patients, [31] other observational studies have shown lower mortality rates in hospitalised patients with COVID-19. [2, 42] Our TSA analysis found that assuming a baseline mortality rate of 20% in this cohort and a RR reduction of 10%, the cumulative Z-curve was within the boundary for futility. This implies that CP in its current state and timing of administration is unlikely to confer survival benefit amongst patients hospitalised with COVID-19, and recruitment of further patients for CP would be futile.

Two interrelated factors could explain the lack of demonstrable efficacy of CP in COVID-19: the serostatus of the recipient and the timing of plasma administration. SARS-CoV-2 viraemia peaks at the first week of illness and viral clearance which follows the primary immune response occurs by 10-14 days.

Beyond 8 days after symptom onset, nearly all patients with COVID-19 had neutralising antibody responses. [43] In our analysis, antibody titres across both arms were reported to be similar, [28] and as many as 80% of patients receiving CP were seropositive at baseline, [14, 16, 31, 40] which could also potentially account for the lack of survival benefit from CP.

Several studies have found that receipt of CP within 72 hours in milder forms of COVID-19 provided significant benefits to survival and disease progression. [18, 44, 45] Of note, two RCTs randomised their patients within three days of severe symptoms, and both did not find any survival benefits. [30, 37] Patients even in the early stages of severe COVID-19 are likely to have been seroconverted, and as such, CP confers no additional benefit. It is interesting to note that the recent COVID-19 Convalescent Plasma in Outpatients (C3PO) trial, which randomised patients to receive relatively high-titre (1:160) CP within 7 days of symptoms, found no significant mortality benefits of CP, which argues against the possibility of better efficacy of CP in patients who are seronegative. A recent Bayesian re-analysis of the RECOVERY trial data suggested some mortality benefit in seronegative patients receiving CP, [46] concordant with a propensity-score matched study investigating CP in patients with immunodeficiency. [47] This may suggest the need to select for recipients who are unable to mount an adequate immune response for transfer of passive immunity and to maximise the effects of CP.

The meta-analysis and TSA are particularly apt as several trials were terminated early, and results were inconclusive. [14] [15] [16] [17] [18] The use of trial sequential analysis allowed us to assess the pooled effect in relation to the required information size, as well as assess futility. As such, the added value of our study lies in the finding that further recruitment of patients is futile in eliciting the effect of CP in patients with severe COVID-19, which previous meta-analyses have not investigated. More importantly, the finding of futility holds massive public health implications, particularly when the delta variant becomes increasingly prevalent. Immense amounts of resources are diverted away from other potentially beneficial therapies, as well as vaccine production. More importantly, patients who received CP therapy have been advised to defer vaccination for at least 90 days which puts a dent in the goal to vaccinate everyone as quickly as possible. [48] We recognise several limitations of our study. A large proportion of patients had severe to critical COVID-19 who received CP approximately a week after the onset of symptoms. The results of our meta-analysis are therefore not completely generalisable to patients with mild and moderate COVID-19 where CP is used within a week of symptom onset, or in patients who are immunocompromised or seronegative at the time of transfusion. [47] This is further compounded by the fact that volumes of CP and antibody neutralising titres were heterogenous across studies. While some studies have suggested a dose-response relationship in CP for COVID-19, [40] we were unable to account for this as we were limited by study-level data, and the fact that various instruments and scales were used to determine antibody titres across the studies. There is also likely some residual uncertainty for these highly select groups of patients. Most studies included in the analysis had some concerns of bias, with one study being rated as high risk of bias. As such, the results of these trials should be interpreted with caution, and the certainty of the evidence is impacted. This is further compounded by inclusion of data from preprint servers, which can in itself introduce bias. Nevertheless, the concerns of bias mostly lay in deviations from the intended intervention, where studies had patients crossover from the control arm to the CP arm. Such deviations from interventions may be unavoidable in the context of the current pandemic, where withholding a potentially lifesaving treatment may be considered unethical. In addition, the assessment of evidence found high certainty for the primary outcome, and the pooled results did not significantly change based on the trim-and-fill procedure. Most of the patients receiving CP have also been subjected to a range of other therapies, which might confound the findings of the RCTs.

In this meta-analysis of over 16000 patients hospitalised with COVID-19, CP did not significantly reduce mortality, nor did it provide any significant benefit for any other clinical outcomes. The pooled effect was within the boundary of futility suggesting further recruitment of patients is unlikely to demonstrate mortality benefit of CP as postulated in patients with severe COVID-19. Nonetheless, its therapeutic use in patients unable to mount an adequate immune response remains undetermined. Rather than determining its effectiveness in COVID-19 in general, further research on CP should be directed in highly select patient groups , and determining which subgroup of patients is most likely to benefit.

All data generated or analysed during this study are included in the published studies and their supplementary information files.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. All authors provided critical conceptual input, interpreted the data analysis, read, and approved the final draft.

All authors declare no competing interests. 

Clinical Characteristics of Coronavirus Disease 2019 in China

ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida

Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis

Receptor Antagonists for Severe Coronavirus Disease 2019: A Meta-analysis of Reconstructed Individual Patient Data from Randomised Controlled Trials

A living WHO guideline on drugs for covid-19

Covid-19: Regeneron's antibody combination cuts deaths in seronegative patients, trial finds

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis

The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Convalescent Plasma for COVID-19: A multicenter

Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial

Convalescent Plasma for COVID-19

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial

Meta-analysis in clinical trials

The Inverse of the Freeman -Tukey Double Arcsine Transformation

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial

Ail Mohamed. Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease

Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, openlabel, platform trial

The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad

Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm

The REMAP-CAP Investigators. Convalescent Plasma in Critically ill Patients with Covid-19

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial

for The. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial

Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients

Intravenous immunoglobulin in neurology--mode of action and clinical efficacy

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG

Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomised controlled trial

COVID-19, C. Consortium. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Summary Document for Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States

Other Covid-19 medications

Sarilumab 354/928 , azithromycin, lopinavir/ritonavir, tocilizumab, anakinra) 11 CP on day 1, 3, and 5 with a total median of 846 ml

The authors acknowledge Ms. Suei Nee Wong from the National University of Singapore for her assistance with the search strategy.

 Figure 4 . Trial sequential analysis for a baseline mortality rate of 20%. As the RECOVERY trial had found no significant benefit at a relative risk reduction (RRR) in mortality of 20%, modelled our TSA based on a 10% RRR in mortality to further elicit the effect of convalescent plasma. The required information size is 17257, and this is not achieved. The cumulative Z-curve (red line) does not cross the boundary for conventional (light-blue dotted lines) or TSAadjusted (upper and lower-most curves) boundaries for benefit or harm. The Z-curve is within the boundary of futility (triangular lines beginning from the middle of the graph).